key: cord-0683945-2s32a15o
authors: Ferguson, Jessica; Murugesan, Kanagavel; Banaei, Niaz; Liu, Anne
title: Interferon-gamma release assay testing to assess COVID-19 vaccination response in a SARS-CoV-2 seronegative patient on rituximab: a case report
date: 2021-06-30
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.06.054
sha: 54755bb2856ab9001b44d8a65f34e1a90e079f08
doc_id: 683945
cord_uid: 2s32a15o

We describe the case of a 44-year-old female on Rituximab for treatment of multiple sclerosis with undetectable SARS-CoV-2 IgG specific antibodies eighteen days after second dose of SARS-CoV-2 vaccine. Interferon-gamma release assay testing for SARS-CoV-2 was positive on day nineteen, demonstrating robust T-cell mediated response despite lack of antibody-mediated response.

Although immunocompromised patients were excluded from the mRNA COVID-19 vaccine clinical trials and made up less than 0.5% of participants in the Janssen / Johnson & Johnson trials, many physician groups are recommending vaccination of these groups. 1-3 Vaccine efficacy in immunocompromised patients is thought to be impaired, with limited data specifically in patients with B cell impairment. 4 Neutralizing antibodies are thought to play a protective role against infection with a decrease in disease severity in patients with early SARS-CoV-2 infection treated with monoclonal antibodies or high-titer convalescent plasma. 5, 6 Spike-specific, nucleocapsid-specific, and neutralizing antibodies are associated with protection against SARS-CoV-2 infection after natural infection. 7 All three vaccines currently available in the U.S. elicit high levels of neutralizing antibodies. 1, 8 The CDC recommends against routinely assessing antibody levels after vaccination. Data are accumulating that patients on immunosuppressive medications exhibit impaired antibody production after COVID-19 vaccination, with concerning implications for vaccine efficacy in this group. 4 Rituximab is one example: it is an anti-CD20 monoclonal antibody which depletes B cells in the treatment of hematologic malignancies and rheumatologic diseases, and it potently impairs antibody production after vaccination.

SARS-CoV-2-specific antibodies are associated with disease severity, with lower titers noted after asymptomatic and mild disease. 9 However, multiple reports of COVID-19 infections in individuals with humoral deficiencies have demonstrated that uneventful recovery can occur in the absence of antibody production. 10 For individuals with impaired antibody production, finding an immunologic correlate of protection is of great interest.

CD4+ and CD8+ T cell responses may contribute to protection against SARS-CoV-2, even in convalescent individuals after asymptomatic or mild infection and in seronegative exposed family members. 11, 12 All three available vaccines elicit Th1-skewed T cell responses. 1, 13 A key component of the Th1 response is production of interferon-gamma (IFN-γ) by T cells. IFNγ release assays (IGRA) are in vitro blood diagnostics used to measure IFN-γ released by antigen-specific T-cells after overnight stimulation with pathogen peptides. Several studies have reported on the performance of IGRA for detection of cellular immune response to SARS-CoV-2. 14 We have demonstrated high IGRA sensitivity in convalescents in the weeks following COVID-19 which remains sensitive up to seven months post infection. 14 SARS-CoV-2 IGRA is offered as a laboratory-developed test at Stanford Health Care clinical laboratories. This test uses a combination of four peptide pools, which includes the corresponding peptides to spike protein, to stimulate CD4+ and CD8+ T cells and assess IFN-γ concentration by automated enzyme-linked immunosorbent assay (ELISA) with a cutoff value of 0.35 IU/mL. 14 In addition to using SARS-CoV-2 IGRA to assess for past infection, SARS-CoV-2 IGRA can also be used to assess cellular immune response post vaccination.

We present the case of a 44-year-old female whose medical history was notable only for multiple sclerosis that was well controlled on rituximab administered at a dose of 500 mg every 

We expect patients receiving B cell depleting agents such as rituximab will have an impaired antibody response to COVID-19 vaccine, as in this case. Despite delaying vaccination until 14 weeks after her last rituximab dose, our patient did not produce a detectable antibody response. More notably, our patient readily produced an antigen-specific T-cell response detectable 19 days after completed vaccination despite having no B cells. The SARS-CoV-2 IGRA provided evidence that this patient mounted a robust cellular immune response after vaccination, similar to findings by others. 15 Currently, although humoral and cellular immune responses may together reduce disease severity, we do not yet know whether a vaccinegenerated T cell response in the absence of antibody production provides protection against Although current guidance recommends temporarily pausing rituximab and other immunosuppression pending COVID-19 vaccination, it is not known whether this practice improves the immunological response. This is an important factor to discuss with patients if delaying therapy could incur risks of disease reactivation and need for corticosteroids which impair both humoral and cellular immunity. In weighing the risks and benefits of reducing or delaying disease modifying agents, the benefits are not yet defined.

There are several limitations in interpreting this case. Without pre-vaccination testing, we cannot rule out that the patient had prior undetected COVID-19 infection producing the positive IGRA. This specific IGRA showed a 10% background positive rate in healthy individuals reflecting either false positive results, asymptomatic SARS-CoV-2 exposure or cross-reactivity with seasonal coronaviruses. 7 The findings of positive SARS-CoV-2 IGRA post-vaccination with negative antibodies in this patient on rituximab with zero B cells suggests that the IGRA should be studied as a possible correlate of protection after COVID-19 mRNA vaccines in patients on immunosuppressive medications. Ethical approval: This work did not require approval by the institutional review board.

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Immunogenicity of a Single Dose of SARS-CoV

Messenger RNA Vaccine in Solid Organ Transplant Recipients

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19

SARS-CoV-2-Associated T-Cell Responses in the Presence of Humoral Immunodeficiency

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses

Interferon-gamma release assay for accurate detection of SARS-CoV-2 T cell response

SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response